Segmentation by type classifies Non‑Rhabdomyosarcoma treatments into distinct therapeutic classes, each shaping the market landscape. Cytotoxic chemotherapy remains the most prevalent type, covering alkylating agents, antimetabolites, and anthracyclines, and underpins roughly 40 % of total spend due to its long‑standing use across disease stages. Targeted agents, such as tyrosine‑kinase inhibitors and angiogenesis blockers, account for about 25 % of the market, reflecting their niche efficacy in molecularly defined subpopulations. Immunotherapeutic products, including PD‑1/PD‑L1 inhibitors and CAR‑T cell platforms, hold a 15 % share, expanding as clinical evidence accumulates. Hormonal and differentiation therapies, though limited to specific sarcoma subtypes, contribute roughly 10 % of revenues, driven by niche indications. Supportive care agents—anti‑emetics, growth factors, and pain management—represent the remaining 10 %, essential for maintaining treatment adherence and quality of life. Collectively, these type categories delineate investment priorities and forecast growth trajectories within the Non‑Rhabdomyosarcoma Treatment market.